Table 1.
Patient | Age, sex | Duration of disease at sampling | Onset, course | MRI | CSF | Extracerebellar involvement | Other autoimmune diseases | VGKC-complex Ab (pM) | CASPR2 Ab score in CBA | Staining on cerebellar slices |
07–223 | 59, F | <3 months | Subacute, progressive | Mild cerebellar atrophy, no temporal lobe changes | Normal, OCB neg | Limbic encephalitis | Thyroid antibodies | 757 | 4 | Pos |
06–26 | 50, F | <3 months | Subacute, progressive | Mild atrophy to severe atrophy | Normal, OCB not determined | None | Sarcoidosis (mediastinal adenopathies), ANA | <100 | 3 | Pos |
02–762 | 35, F | <3 months | Acute, full recovery | Normal | NA | NA | NA | <100 | 1 | Neg |
A383 | 54, M | 5 years | Fast progressing | NA | NA | Yes | NA | <100 | 2.5 | NA |
A425 | 55, F | 14 years | Subacute, progressive | Normal | Normal | None | Thyroid disease | <100 | 2 | Pos |
A327 | 58, F | 9 years | Chronic, progressive | Normal | ND | None | No | <100 | 2 | Neg |
A386 | 59, F | 8 years | Chronic, stable | ND | ND | None | No | <100 | 1 | Neg |
A220 | 68, F | 9 years | Subacute, progressive | Small vessel disease | ND | Mild bradykinesia | No | <100 | 1 | Pos |
A201 | 76, F | NA | Acute/subacute | NA | NA | NA | NA | <100 | 1 | NA |
The serum samples were obtained either at presentation or after several years. The majority of patients had subacute onset with slowly progressive disease, except for two, who had acute onset with full recovery. Four additional patients had low positive antibodies against voltage-gated calcium channels (85–122 pM; nv <45 pM), two had VGKC-complex antibodies (186 pM, 168 pM) and one patient had high titres of GAD antibodies (4000 U/ml; nv <1 U/ml). Onconeural antibodies were negative in all, and tumours were not found. Sera 07–223, 06–26, 02–762 were from the Spanish ataxia cohort; all other sera were from the Welsh idiopathic ataxia cohort.
Ab, antibody; ANA, antinuclear antibody; CBA, cell-based assay; NA, not applicable; ND, not determined; Neg, negative; OCB, oligoclonal bands; Pos, positive.